{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:47:39Z","timestamp":1761630459950},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1963,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1111\/j.1524-4733.2007.00243.x","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T13:07:21Z","timestamp":1185023241000},"page":"259-271","source":"Crossref","is-referenced-by-count":33,"title":["Advanced Cutaneous Malignant Melanoma: A Systematic Review of Economic and Quality-of-Life Studies"],"prefix":"10.1016","volume":"11","author":[{"given":"Richard P.","family":"Cashin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcio","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel E.H.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia K.","family":"Corey-Lisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Einarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1524-4733.2007.00243.x_bib10","series-title":"Surveillance, Epidemiology, and End Results (SEER) Program","author":"Surveillance Research Program, Cancer Statistics Branch","year":"2005"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2004.05708.x","article-title":"Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma","volume":"150","author":"Lens","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib30","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","author":"Crosby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib50","first-page":"193","article-title":"Prognostic factors in 1521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1998.16.3.1103","article-title":"Prognostic factors for survival of patients treated systemically for disseminated melanoma","volume":"16","author":"Eton","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib70","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/00019053-200422090-00002","article-title":"Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma","volume":"22","author":"Crott","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib80","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D","article-title":"A new American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"88","author":"Balch","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib90","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00019053-199712060-00008","article-title":"Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995)","volume":"12","author":"Iskedjian","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1524-4733.2004.74005.x","article-title":"Cost-utility of adjuvant high-dose interferon alpha therapy in Stage III cutaneous melanoma in Quebec","volume":"7","author":"Crott","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.2000.18.7.1474","article-title":"Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0039-6060(03)00275-7","article-title":"Cost-effectiveness of sentinel lymph node biopsy in thin melanomas","volume":"134","author":"Agnese","year":"2003","journal-title":"Surgery"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.bjc.6600428","article-title":"Primary staging and follow-up in melanoma patients\u2014monocenter evaluation of methods, costs and patient survival","volume":"87","author":"Hoffmann","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib140","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1052::AID-CNCR7>3.0.CO;2-B","article-title":"Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences. A cost-effectiveness analysis","volume":"70","author":"Mooney","year":"1997","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib150","series-title":"Guidelines for the evaluation of health technologies","year":"2006"},{"issue":"22","key":"10.1111\/j.1524-4733.2007.00243.x_bib160","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"15","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00520-002-0419-3","article-title":"The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma","volume":"11","author":"Beusterien","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/1099-1611(200007\/08)9:4<283::AID-PON460>3.0.CO;2-N","article-title":"Coping with metastatic melanoma: the last year of life","volume":"9","author":"Brown","year":"2000","journal-title":"Psychooncology"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib190","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1200\/JCO.1999.17.7.2256","article-title":"Psychosocial predictors of survival in metastatic melanoma","volume":"17","author":"Butow","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib200","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0959-8049(93)90115-V","article-title":"Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma","volume":"29A","author":"Coates","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00008390-200209000-00013","article-title":"Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumor-derived vaccine","volume":"12","author":"Cohen","year":"2002","journal-title":"Melanoma Res"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib220","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1081\/CNV-120025084","article-title":"Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine","volume":"21","author":"Kiebert","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib230","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00435223","article-title":"The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique","volume":"2","author":"Sigur\u00f0ardottir","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pon.2960040406","article-title":"Quality of life and ethics: opinions about chemotherapy among patients with advanced melanoma, next of kin and care-providers","volume":"4","author":"Sigur\u00f0ardottir","year":"1995","journal-title":"Psychooncology"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib260","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/02841869609098495","article-title":"Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy","volume":"35","author":"Sigur\u00f0ardottir","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00433922","article-title":"Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters","volume":"5","author":"Sigur\u00f0ardottir","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib280","first-page":"458","article-title":"Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib290","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib300","first-page":"133","article-title":"Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial","volume":"3","author":"Thomson","year":"1993","journal-title":"Melanoma Res"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1524-4733.2004.71246.x","article-title":"Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?","volume":"7","author":"Tengs","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib320","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/106002809502907-805","article-title":"Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals","volume":"29","author":"Bradley","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1524-4733.2007.00243.x_bib330","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1345\/aph.1G296","article-title":"Quality assessment of published health economic analyses from South America","volume":"40","author":"Machado","year":"2006","journal-title":"Ann Pharmacother"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510605190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510605190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T08:47:24Z","timestamp":1587804444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510605190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S1098301510605190"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00243.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}